{"disease":{"id":"diarrhea","name":"Diarrhea","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":5},"drugs":{"marketed":[{"drug_id":"rifaximin","indication_name":"Irritable bowel syndrome with diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xifaxan","generic_name":"rifaximin","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":"1500","mechanism":null},{"drug_id":"rifaximin","indication_name":"Diarrhea due to E. Coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xifaxan","generic_name":"rifaximin","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":"1500","mechanism":null},{"drug_id":"octreotide","indication_name":"Diarrhea from Pancreatic VIPoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandostatin","generic_name":"OCTREOTIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":75,"revenue":"305","mechanism":"Sandostatin works by mimicking the natural hormone somatostatin to inhibit the release of various hormones and growth factors."},{"drug_id":"phenolphthalein","indication_name":"Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phthalin","generic_name":"PHENOLPHTHALEIN","company_name":"","drug_phase":"marketed","molecular_target":"Thymidylate synthase, Thymidylate synthase","drug_class":"phenolphthalein","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"potassium-bicarbonate","indication_name":"Prevention of Potassium Depletion - Diarrheal States","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"POTASSIUM BICARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"eluxadoline","indication_name":"Irritable bowel syndrome with diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viberzi","generic_name":"ELUXADOLINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"mu-Opioid Receptor Agonist [EPC]","quality_score":48,"revenue":null,"mechanism":"Viberzi works by activating the mu-opioid receptor in the gut to slow down bowel movements and reduce diarrhea."},{"drug_id":"vancomycin","indication_name":"Clostridium difficile diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vancocin","generic_name":"vancomycin","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"crofelemer","indication_name":"Non-infective diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mytesi","generic_name":"CROFELEMER","company_name":"Napo Pharms Inc","drug_phase":"marketed","molecular_target":"Anoctamin-1","drug_class":"Antidiarrheal [EPC]","quality_score":10,"revenue":null,"mechanism":"Mytesi works by blocking the action of a specific protein called anoctamin-1, which helps regulate the movement of water and electrolytes in the intestines."},{"drug_id":"bismuth-subsalicylate","indication_name":"Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pepto-Bismol","generic_name":"bismuth subsalicylate","company_name":"Generic (Procter & Gamble)","drug_phase":"marketed","molecular_target":"Cyclooxygenase","drug_class":"Bismuth [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"xifaxan","indication_name":"Diarrhea due to E. Coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xifaxan","company_name":"Children's Hospital Los Angeles","drug_phase":"discontinued","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"xifaxan","indication_name":"Irritable bowel syndrome with diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xifaxan","company_name":"Children's Hospital Los Angeles","drug_phase":"discontinued","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"alosetron","indication_name":"Irritable bowel syndrome with diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotronex","generic_name":"ALOSETRON","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A","drug_class":"Serotonin-3 Receptor Antagonist","quality_score":66,"revenue":null,"mechanism":"Lotronex works by blocking serotonin receptors in the gut to slow down bowel movements."},{"drug_id":"ciprofloxacine","indication_name":"Diarrhea due to E. Coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with diarrhea.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"morphine","indication_name":"Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"mer","indication_name":"Temporary relief of diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mer Detox 6019","generic_name":"mer","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"diphenoxylate","indication_name":"Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lomotil","generic_name":"DIPHENOXYLATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Antidiarrheal","quality_score":41,"revenue":null,"mechanism":""},{"drug_id":"morphine-sulfate","indication_name":"Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"difenoxin","indication_name":"Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Motofen","generic_name":"DIFENOXIN","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Antidiarrheal","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Diarrhea due to E. Coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Diarrhea due to E. Coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Diarrhea due to E. Coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rifaximine","indication_name":"Diarrhea due to E. Coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rifaximine","company_name":"Ain Shams University","drug_phase":"phase_2","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rifaximine","indication_name":"Irritable bowel syndrome with diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rifaximine","company_name":"Ain Shams University","drug_phase":"phase_2","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Diarrhea due to E. Coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xermelo","indication_name":"Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xermelo","company_name":"TerSera Therapeutics LLC","drug_phase":"marketed","molecular_target":"Tryptophan 5-hydroxylase 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"loperamide","indication_name":"Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imodium","generic_name":"loperamide","company_name":"Johnson & Johnson (McNeil Consumer Healthcare)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Cocaine esterase, D(4) dopamine receptor","drug_class":"Antidiarrheal (peripheral opioid agonist)","quality_score":null,"revenue":null,"mechanism":"Peripheral mu-opioid receptor agonist that slows intestinal motility and increases fluid absorption without crossing the blood-brain barrier."},{"drug_id":"loperamide","indication_name":"Diarrhea Secondary to Inflammatory Bowel Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imodium","generic_name":"loperamide","company_name":"Johnson & Johnson (McNeil Consumer Healthcare)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Cocaine esterase, D(4) dopamine receptor","drug_class":"Antidiarrheal (peripheral opioid agonist)","quality_score":null,"revenue":null,"mechanism":"Peripheral mu-opioid receptor agonist that slows intestinal motility and increases fluid absorption without crossing the blood-brain barrier."},{"drug_id":"lysine","indication_name":"Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"L-Lysine","generic_name":"LYSINE","company_name":"Advanced Accelerator Applications","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"lysine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"loperamide","indication_name":"Traveler's diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imodium","generic_name":"loperamide","company_name":"Johnson & Johnson (McNeil Consumer Healthcare)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Cocaine esterase, D(4) dopamine receptor","drug_class":"Antidiarrheal (peripheral opioid agonist)","quality_score":null,"revenue":null,"mechanism":"Peripheral mu-opioid receptor agonist that slows intestinal motility and increases fluid absorption without crossing the blood-brain barrier."},{"drug_id":"mer","indication_name":"Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mer Detox 6019","generic_name":"mer","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"telotristat-ethyl","indication_name":"Carcinoid Syndrome Diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TELOTRISTAT ETHYL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":37,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07436104","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":72564,"lead_sponsor_name":"MAHAN Trust","has_results":false},{"nct_id":"NCT04020965","title":"Drinking Water Chlorination and Child Survival in Rural Kenya","phase":"NA","overall_status":"COMPLETED","enrollment_count":46212,"lead_sponsor_name":"Tufts University","has_results":false},{"nct_id":"NCT06560853","title":"Evaluation of a Comprehensive School Health Programme in Zambia","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28700,"lead_sponsor_name":"London School of Economics and Political Science","has_results":false},{"nct_id":"NCT05123378","title":"Liberia National Community Health Assistant (NCHA) Program and Under-five Mortality","phase":"NA","overall_status":"UNKNOWN","enrollment_count":23702,"lead_sponsor_name":"Last Mile Health","has_results":false},{"nct_id":"NCT05247333","title":"Implementation of a Minor Ailment Service in Community Pharmacy Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":20987,"lead_sponsor_name":"Universidad de Granada","has_results":false},{"nct_id":"NCT04672577","title":"Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Patricia Schlagenhauf","has_results":false},{"nct_id":"NCT03536286","title":"Asili Evaluation in the Democratic Republic of Congo","phase":"NA","overall_status":"COMPLETED","enrollment_count":9999,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT06149715","title":"Water Filter Study in Ciudad Victoria","phase":"NA","overall_status":"COMPLETED","enrollment_count":9887,"lead_sponsor_name":"Aquora Research & Consulting, LLC","has_results":false},{"nct_id":"NCT06047821","title":"Enterics for Global Health (EFGH)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9800,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03130114","title":"Antibiotics for Children With Severe Diarrhoea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":8268,"lead_sponsor_name":"World Health Organization","has_results":false},{"nct_id":"NCT05024890","title":"The Impact of a School-based WASH Intervention on Child Health and School Attendance in Addis Ababa, Ethiopia","phase":"NA","overall_status":"COMPLETED","enrollment_count":7072,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT04838587","title":"An Epidemiological Surveillance Study to Determine the Incidence of ETEC in Children and Infants in Lusaka","phase":"","overall_status":"COMPLETED","enrollment_count":6828,"lead_sponsor_name":"Centre for Infectious Disease Research in Zambia","has_results":false},{"nct_id":"NCT07272122","title":"Reducing Filth Fly Populations and Transmission of Diarrhoeal Pathogens in Harsh Settings","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":5676,"lead_sponsor_name":"The Mentor Initiative","has_results":false},{"nct_id":"NCT03154229","title":"Evaluation of a mHealth Platform for Diarrheal Disease Decision-support","phase":"NA","overall_status":"COMPLETED","enrollment_count":4975,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT03078842","title":"Zinc Dosing Trial - Does Dose Reduction Reduce Side Effects But Retain Efficacy in Diarrhoea Management","phase":"NA","overall_status":"COMPLETED","enrollment_count":4500,"lead_sponsor_name":"Ayesha De Costa","has_results":false},{"nct_id":"NCT03208725","title":"Childhood Acute Illness and Nutrition Network","phase":"","overall_status":"UNKNOWN","enrollment_count":4335,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05766826","title":"Coupons for Safe Water Project","phase":"NA","overall_status":"RECRUITING","enrollment_count":3468,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT06003816","title":"Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)","phase":"NA","overall_status":"RECRUITING","enrollment_count":3140,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT03423615","title":"Lay Fieldworker Led School Health Program for Rural Primary Schools","phase":"NA","overall_status":"COMPLETED","enrollment_count":2909,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT05166850","title":"Preventative Intervention for Cholera for 7 Days","phase":"NA","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT03406793","title":"Zinc-MNP Trial for Prevention of Diarrhea and Promotion of Linear Growth","phase":"NA","overall_status":"COMPLETED","enrollment_count":2886,"lead_sponsor_name":"UCSF Benioff Children's Hospital Oakland","has_results":false},{"nct_id":"NCT04008134","title":"Cholera-Hospital-Based-Intervention-for-7-days","phase":"NA","overall_status":"COMPLETED","enrollment_count":2626,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT04833790","title":"What Drives Poor Care for Child Diarrhea: A Standardized Patient Experiment","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2451,"lead_sponsor_name":"RAND","has_results":false},{"nct_id":"NCT03778125","title":"Multidrug Resistant Shigella Infection in Bangladesh","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT06882070","title":"ROTA-biotic: Measuring the Impact of Rotavirus Vaccines on Paediatric Antibiotic Usage","phase":"","overall_status":"COMPLETED","enrollment_count":1600,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT06498817","title":"Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT03709368","title":"Software Interventions for Improving Hand Washing and Sanitation in Rural Tanzania: an Impact Evaluation","phase":"NA","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Centre for Evidence-Based Practice, Belgium","has_results":false},{"nct_id":"NCT05322694","title":"Clinical Decision Rules in the Emergency Department to Improve the Management of Acute Respiratory Infection and Acute Infectious Diarrhea","phase":"","overall_status":"COMPLETED","enrollment_count":1474,"lead_sponsor_name":"Simon Berthelot","has_results":false},{"nct_id":"NCT02414399","title":"Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":1400,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT04212403","title":"Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1350,"lead_sponsor_name":"Jessa Hospital","has_results":false},{"nct_id":"NCT04312906","title":"A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa","phase":"","overall_status":"COMPLETED","enrollment_count":1334,"lead_sponsor_name":"Centre for Infectious Disease Research in Zambia","has_results":false},{"nct_id":"NCT02765217","title":"Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1325,"lead_sponsor_name":"Eskisehir Osmangazi University","has_results":false},{"nct_id":"NCT04580212","title":"Poultry Management and Child Diarrhea in Uganda","phase":"NA","overall_status":"COMPLETED","enrollment_count":1307,"lead_sponsor_name":"North Carolina State University","has_results":false},{"nct_id":"NCT04335877","title":"Effect of Prompting the Supply of Zinc/LO-ORS Co-packs in the Private Sector Plus BCI on Childhood Diarrhea Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":1245,"lead_sponsor_name":"Nutrition International","has_results":false},{"nct_id":"NCT06363890","title":"Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Lumen Bioscience, Inc.","has_results":false},{"nct_id":"NCT07338643","title":"The Auxiliary Effect of Artificial Intelligence in the Detection of Precancerous Lesions in Proximal Colon Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Limian Er","has_results":false},{"nct_id":"NCT03990220","title":"A Nutritional Trial on Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda","phase":"","overall_status":"UNKNOWN","enrollment_count":1116,"lead_sponsor_name":"VU University of Amsterdam","has_results":false},{"nct_id":"NCT03174015","title":"Sanitation Demand Creation in Peri-Urban Slums of Lusaka, Zambia","phase":"NA","overall_status":"COMPLETED","enrollment_count":1085,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT03851835","title":"Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1030,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT03394040","title":"Point-of-Use Pathogen Identification Tool for Diarrhea","phase":"","overall_status":"TERMINATED","enrollment_count":1000,"lead_sponsor_name":"National Institute of Nursing Research (NINR)","has_results":false},{"nct_id":"NCT07234448","title":"Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Liaquat University of Medical & Health Sciences","has_results":false},{"nct_id":"NCT04826991","title":"Wells and Enteric Disease Transmission","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":908,"lead_sponsor_name":"Temple University","has_results":false},{"nct_id":"NCT03468114","title":"The Safe Start Trial - Kisumu, Kenya","phase":"NA","overall_status":"COMPLETED","enrollment_count":880,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT04605783","title":"Trial to Evaluate Dietary Supplements to Maintain Gut Health During Travel","phase":"NA","overall_status":"COMPLETED","enrollment_count":851,"lead_sponsor_name":"Henry M. Jackson Foundation for the Advancement of Military Medicine","has_results":false},{"nct_id":"NCT07158632","title":"Effects of Multiple Interventions on Under-Five Diarrhea","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":840,"lead_sponsor_name":"Jimma University","has_results":false},{"nct_id":"NCT03703336","title":"Phase III Study of Liquid Formulation of ROTAVIN","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":825,"lead_sponsor_name":"Center for Research and Production of Vaccines and Biologicals, Vietnam","has_results":true},{"nct_id":"NCT03587389","title":"Response to Rotavirus Vaccine in Infants in Ho Chi Minh City in Vietnam","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":818,"lead_sponsor_name":"Oxford University Clinical Research Unit, Vietnam","has_results":false},{"nct_id":"NCT02612649","title":"Special Drug Use Surveillance of Irribow in Female Patients","phase":"","overall_status":"COMPLETED","enrollment_count":793,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT03176914","title":"Testing the Effectiveness of a Modified Community Model in Improving Child Health Outcomes in Mashonaland East, Zimbabwe","phase":"NA","overall_status":"COMPLETED","enrollment_count":765,"lead_sponsor_name":"University of Zimbabwe","has_results":false},{"nct_id":"NCT03729219","title":"Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":749,"lead_sponsor_name":"Scandinavian Biopharma AB","has_results":false}],"total":50},"guidelines":[{"drug_id":"mer","guideline_body":"FDA label","recommendation":"For the temporary relief of diarrhea.","line_of_therapy":"any","evidence_grade":"C","guideline_year":null}],"source":"Drug Landscape verified database"}